Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Crystagen peptide icon, one bubble per amino acidCrystagen3 residuesEDPEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Crystagen

Beginner tier: 20 mg, daily · 4w on / 12w off · community consensus

ImmuneResearch
~0.5-2 hours half-life (estimated)·Oral

Also known as: Crystagen, Kristagen

Three amino acids. That's all Crystagen is. Glu-Asp-Pro, a synthetic tripeptide pulled from Thymalin, the Soviet-era thymus extract that's been in Russian clinical use since 1982. In one clinical observation of elderly patients, oral Crystagen normalized immunograms in 82% of cases after a 30-day course. That number sounds good until you learn it comes from a single research group at the St. Petersburg Institute of Bioregulation and Gerontology, with no independent Western replication. The peptide is taken as oral capsules (20 mg, once daily) for 10 to 30 days, repeated two to three times per year. Longevity protocol users stack it with Epithalon for combined thymic and pineal axis coverage.

What Is Crystagen?

Four published studies, one research group, and an 82% immunogram normalization rate that nobody outside St. Petersburg has tried to replicate. That's the honest picture of Crystagen (Glu-Asp-Pro, molecular weight ~359 Da, No CAS number assigned), a synthetic tripeptide isolated from Thymalin at the Khavinson Institute of Bioregulation and Gerontology.

The mechanism targets immune cell gene expression. Crystagen's Glu-Asp dipeptide core binds DNA promoter regions in thymic epithelial cells and lymphocytes, promoting heterochromatinization of aged chromatin. In thymocyte assays, Khavinson's group tracked shifts in CD3+ and CD4+ T-cell populations and normalization of CD4+/CD8+ ratios [1]. In gamma-irradiated rat models, the peptide preserved thymic cortex-medulla architecture and maintained thymocyte proliferation.

Practically, Crystagen is an oral capsule. One to two capsules daily (20 to 40 mg), taken 15 to 20 minutes before a meal, for courses of 10 to 30 days. Courses repeat two to three times per year with three to six month breaks between them. Oral bioavailability sits at an estimated 1 to 10% based on general tripeptide pharmacokinetics; Khavinson's group argues that even minimal absorption triggers gene-regulatory cascades that persist beyond the dosing period.

Community experience is thin. Fewer than 10 independent Reddit threads discuss Crystagen. Most user reports come from product-page testimonials and a single longevity blog. Anecdotal benefits center on immune resilience during cold and flu season, though separating this from placebo is essentially impossible without bloodwork. The peptide's research base is real but narrow, and the single-group dependency is the biggest scientific limitation.

How Crystagen Works

Crystagen belongs to the Khavinson class of ultrashort peptides proposed to regulate gene expression through direct DNA interaction. The peptide's tissue specificity for immune cells appears to come from its Glu-Asp dipeptide core, which binds specific gene promoter regions in thymic epithelial cells and blood lymphocytes.

In the spleen, Crystagen activates B-cell immunity without affecting cellular renewal processes during aging. This distinguishes it from Vilon (Lys-Glu), which primarily targets T-helper cells [2]. In thymocyte assays, the peptide influences T-cell differentiation markers. Khavinson's group reported shifts in CD3+ and CD4+ populations and normalization of CD4+/CD8+ ratios in elderly subjects [1].

At the epigenetic level, Crystagen promotes heterochromatinization in aged lymphocytes. Chromatin condensation patterns in blood lymphocytes from elderly subjects shifted toward younger profiles after a full treatment course [3]. This suggests the peptide can alter gene accessibility states, though the downstream functional consequences of these chromatin changes have not been mapped in detail.

The proposed model is that short peptide courses trigger lasting epigenetic reprogramming that persists for months. This differs from receptor desensitization or hormonal axis feedback models. The peptide doesn't accumulate; it initiates a cascade.

Crystagen Benefits

  • Crystagen benefits center on thymic immune support and age-related immune normalization, though the evidence base remains narrow.
  • - Immunogram normalization in 82% of elderly patients after a 30-day oral course, compared to 56% in the control group (Khavinson clinical observation, St. Petersburg Institute) - Preserved thymic cortex-medulla architecture in gamma-irradiated rat models, maintaining thymocyte proliferation rates that collapsed in untreated controls - Activated proliferation of human thymic epithelial cells in vitro; users over 50 may find this relevant given age-related thymic involution - Inhibited K-562 human erythromyelosis tumor cell proliferation in vitro [1], though no in vivo oncology data exists - Oral capsule format with no injections, no reconstitution, and no refrigeration needed - Community reports from longevity forums describe improved cold and flu season resilience within one to two courses, though independent verification is absent

Crystagen: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 5 key studies·Research only

Preclinical immune modulation data from a single Russian research group; 82% immunogram normalization reported in one elderly-patient clinical observation.

Dosing studied: 10–20 mg/day oral (1–2 capsules), 10–30 day courses, 2–3× per year
Read the evidence (key study, limitations)

No independent Western replication exists. Oral bioavailability estimated at 1–10% with no direct PK studies.

Key Study

Khavinson et al. 2002 (PMID 12420072): thymocyte blast transformation and CD3+/CD4+ signal transduction; Khavinson et al. 2004 (PMID 15085253): lymphocyte heterochromatinization in elderly subjects

Limitations

All published data originates from a single research group (Khavinson Institute, St. Petersburg). No RCTs, no independent replication, no Western peer review, no direct PK studies on Crystagen itself. Oral bioavailability is estimated by analogy to tripeptide class pharmacokinetics, not directly measured.

Community Experience
Weak
2.8/5
Based on <10 independent Reddit/forum threads

Extremely limited independent user reports: most accounts appear on commercial product pages.

Community dosing: 1–2 capsules (20–40 mg) daily for 10–30 days per course
Read the reports (what users report 3, common issues 4)

Anecdotal immune resilience during cold/flu season and nootropic clarity (when stacked with other Khavinson bioregulators) are the primary reported benefits.

What users report (3)
  • Anecdotal immune resilience during cold/flu season (product-page testimonials, community reports)
  • Reported "nootropic clarity" when stacked with other Khavinson bioregulators (e.g., Epithalon, Pinealon)
  • Oral capsule convenience versus injectable thymic peptides (TA-1, Thymalin)
Common issues (4)
  • Minimal independent user reports: almost no firsthand accounts outside commercial product pages and longevity forums
  • All research from a single group; community has low confidence in evidence quality
  • Capsule mg-per-unit unclear across products (10 mg vs 20 mg capsules, depending on the brand)
  • No acute or near-term noticeable effects expected: frustration with perceived lack of response is common
Partially Aligned

Science and community both identify immune modulation as the primary use case. Community anecdotes extend to nootropic/clarity effects not reported in any published study. Dosing broadly matches the Khavinson 1–2 capsule/day protocol, though community use sometimes defaults to continuous daily use rather than the structured 10–30 day course model.

Crystagen Dosage Guide

CommunityKhavinson Institute protocol
LevelDoseFrequency
Beginner20 mgDaily
Moderate40 mgDaily
Aggressive20 mg2x Daily
Note:

Crystagen comes as oral capsules, so there's no reconstitution math. Each capsule contains 20 mg of the synthetic tripeptide (Glu-Asp-Pro). Take one capsule 15 to 20 minutes before a meal, once daily, for 30 days. Swallow whole with water.

The thing most beginners miss: you won't feel anything. Crystagen works through epigenetic changes in immune cells that accumulate over 15 to 30 days. Lack of immediate effect is normal, not a sign of a bad product.

Bloodwork is the only way to know if it worked. Get a CBC with differential and CD4+/CD8+ ratio before starting, then retest four to six weeks after finishing the course. Subjective "feeling healthier" is unreliable for immune peptides.

Khavinson-affiliated capsules carry Russian-language primary labeling. Avoid the injectable vials sold online as research peptides; that format has zero clinical backing.

Cycling Protocol

On Period
4 weeks
Off Period
12 weeks

Standard Khavinson bioregulator protocol: 10-30 day courses repeated 2-3 times per year. A common regimen is 1-2 capsules daily for 30 days, then a 3-6 month break.

Calculate your Crystagen dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Crystagen Protocols by Goal

beginnerCommunity30 days on, 3–6 months off; repeat 2–3× per year
Treatment course
Wk 4 (28–30 days)
20 mg (1 capsule) · Once daily · Oral

Expected: Potential normalization of CD4+/CD8+ ratio and lymphocyte counts after a full 30-day course per Khavinson data; subjective immune resilience during cold/flu season per community reports

Monitor: Baseline CBC with differential and CD4+/CD8+ ratio before starting; retest 4–6 weeks after course completion to assess objective immune response

How to Use Crystagen

  1. 1
    Confirm your capsules are 20 mg Crystagen

    Check for Russian-language labeling and lot number on the packaging.

  2. 2
    Take one capsule orally, 15 to 20 minutes before a meal

    Swallow whole with water. Do not crush or open the capsule.

  3. 3
    Dose once daily, same time each morning if possible

    The standard beginner course is one capsule (20 mg) per day.

  4. 4
    Continue for 30 consecutive days without interruption

    Do not skip days or double up on missed doses.

  5. 5
    After completing the 30-day course, stop

    The standard off-period is three to six months. During this break, the epigenetic changes from the course are expected to persist.

  6. 6
    Repeat the course two to three times per year

    An intermediate protocol starts with one capsule daily for two weeks, then increases to two capsules (40 mg) daily for the remaining two weeks.

  7. 7
    Step 7

    Storage: keep capsules at room temperature (15 to 25 degrees Celsius) in a dry place, away from direct sunlight. No refrigeration needed.

Alternative Routes

Oral capsule

1–2 capsules (20–40 mg) once daily, 15–20 minutes before a meal

Standard Khavinson capsule format. Bioavailability estimated at 1–10% by analogy to tripeptide class; Khavinson argues this is sufficient to trigger gene-regulatory cascades without high systemic concentrations.

Sublingual drops

1 mL/day (10 mg/mL solution) administered as 5–6 drops, 3–4 times daily per product label instructions

Sold as an imported bioregulator product. Sublingual bypass of first-pass metabolism theoretically improves bioavailability over oral capsule, but this has not been studied for Crystagen. Timing and dosing protocol differs from the oral capsule format.

Injectable (subcutaneous)

No established injectable dosing protocol; vials sold as research use only with no clinical dosing reference

Injectable format is not a Khavinson Institute product and has no clinical precedent. Community occasionally uses based on dosing models extrapolated from other injectable thymic peptides: entirely speculative. Significantly higher risk profile than oral/sublingual.

Crystagen Stacking Protocols

Works With

Avoid

Immunosuppressants (cyclosporine, tacrolimus, prednisone, mycophenolate)

Crystagen's immune-activating effects directly oppose immunosuppressive therapy. Risk of undermining transplant rejection protection or active autoimmune disease management.

Do not combine
Checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab)

Combined immune activation from checkpoint inhibition + Crystagen is completely unstudied. Theoretical compounding of immune-related adverse events (irAEs) in oncology patients.

Do not combine

Estimated Cost

Brand Price
~$45–$65 for 20 capsules (one 30-day course at 1 cap/day), Khavinson-affiliated Russian capsules
Compounded
Research-grade injectable vials: ~$35–$50 for 10 mg; ~$40–$55 for 20 mg: not therapeutic equivalents to the oral bioregulator

Pricing updated 2026-04-09

Crystagen Side Effects

The biggest concern with Crystagen isn't a specific side effect. It's the absence of data. No adverse effects directly attributable to Crystagen have been reported in any published study, but the total safety database is small (five publications, all from a single group, with limited patient counts).

Autoimmune exacerbation is the most clinically relevant theoretical risk. Crystagen activates T-cell and B-cell populations and shifts CD4+/CD8+ ratios. In someone with subclinical or active autoimmune disease, this immune stimulation could unmask or worsen autoimmune flares. Joint swelling, unexplained rash, or new symptom patterns during a course warrant immediate discontinuation and medical evaluation before restarting.

Gastrointestinal discomfort is possible with the oral capsule formulation. Taking Crystagen 15 to 20 minutes before a meal (not on a fully empty stomach) reduces GI irritation. This is the most commonly reported practical issue in user accounts, though severity appears mild.

Immunosuppressant interference is a serious drug interaction concern. Crystagen's immune-activating effects directly oppose cyclosporine, tacrolimus, and similar immunosuppressive therapy. Organ transplant recipients on immunosuppression should not use Crystagen. The risk of undermining transplant rejection protection is real and straightforward.

Checkpoint inhibitor interactions are completely unstudied. For oncology patients on pembrolizumab, nivolumab, or ipilimumab, adding Crystagen introduces combined immune activation with unknown immune-related adverse event profiles. This combination should be avoided.

Oral bioavailability uncertainty adds another layer. Absorption is estimated at 1 to 10% based on tripeptide class pharmacokinetics, not direct measurement. Batch-to-batch variation (capsules range from 10 mg to 20 mg depending on the product) means actual dose delivered to systemic circulation is unpredictable.

Pregnancy and breastfeeding are absolute contraindications. No reproductive safety data exists for Crystagen. Given the peptide's mechanism of modulating immune cell gene expression, use during pregnancy or breastfeeding is not appropriate.

Quality control is a practical safety concern. Capsules from Khavinson-affiliated manufacturers have established manufacturing history. Research-grade injectable vials represent a separate, higher-risk supply chain with no clinical precedent for the injectable format. Avoid injectable versions; the oral capsule is the only format with clinical backing.

Stop the course and seek medical evaluation if: new joint swelling or unexplained rash appears, fever develops without an obvious infection source, or any autoimmune symptom pattern emerges. Do not start a new course during active infection or fever.

Common Issues & Solutions

No acute effects expected: Crystagen's mechanism is epigenetic; immune gene expression changes accumulate over 15–30 days. Lack of immediate effect is normal and not a sign of product failure.

Hold course during active infection: defer starting a new course until fully recovered; immune modulation during active infection or fever is unstudied and could theoretically disrupt the normal acute immune response.

GI discomfort: always take 15–20 minutes before a meal (not on a fully empty stomach) to minimize GI irritation from the capsule formulation.

Subjective immune benefit is unreliable: bloodwork (CBC with differential, CD4+/CD8+ ratio) is needed to objectively assess response. Do not judge efficacy by feeling alone.

Autoimmune concern: any new joint swelling, unexplained rash, or symptom flare during a course warrants immediate discontinuation and medical evaluation before restarting.

Ask AI about this page

Ask AI for a second opinion on Crystagen dosing and side effects

Contraindications

  • Active autoimmune disease — immune modulation could worsen autoimmune flares
  • Organ transplant recipients on immunosuppressive therapy
  • Pregnancy or breastfeeding — no reproductive safety data exists
  • Known hypersensitivity to any component of the capsule formulation

Drug Interactions

  • Immunosuppressants (cyclosporine, tacrolimus) — Crystagen's immune-stimulating effects may counteract immunosuppressive therapy
  • Other thymic peptides (Thymosin Alpha 1, Thymalin) — additive immune stimulation is possible
  • Checkpoint inhibitors — combined immune activation effects are unstudied
  • Crystagen's immune-activating effects directly oppose immunosuppressive therapy. Risk of undermining transplant rejection protection or active autoimmune disease management.

Product Quality

Recommended Monitoring

TestWhenTarget
CBC with differential (absolute lymphocyte count)Baseline before course; repeat 4–6 weeks after course completionNormal absolute lymphocyte count 1.0–4.8 × 10⁹/L (age-adjusted reference ranges apply)
CD4+/CD8+ T-cell ratio (flow cytometry)Baseline and end of course (day 30)Normal CD4+/CD8+ ratio: 1.5–2.5; values <1.0 indicate significant immune suppression
ANA (antinuclear antibody) screenBaseline; repeat only if new autoimmune symptoms emerge during or after courseNot listed
CBC with differential (absolute lymphocyte count)

Primary objective measure of Crystagen immune effect; lymphocyte normalization is the claimed clinical endpoint in Khavinson literature

CD4+/CD8+ T-cell ratio (flow cytometry)

Key immune parameter reported in Khavinson studies; Crystagen specifically claimed to normalize this ratio in elderly individuals

ANA (antinuclear antibody) screen

Immune activation via Crystagen carries theoretical risk of unmasking or exacerbating subclinical autoimmune conditions

Crystagen Before and After

Days 1-5

Course initiation. No outward immune changes expected in this early window.

Days 5-15

Short peptides begin influencing gene expression in immune cells. Subtle shifts in immune cell populations may begin, though unlikely to be noticeable without bloodwork.

Days 15-30

End of standard course. The 82% immunogram normalization figure was observed after full treatment courses in elderly patients.

Months 1-6
post-course

The Khavinson theory holds that short peptide effects persist well beyond the dosing period. The off-cycle allows assessment of whether immune improvements are maintained.

What to Expect

Days 1 to 5, Course initiation: Nothing happens that you can feel. The peptide is beginning to interact with gene promoter regions in immune cells per Khavinson's epigenetic model, but measurable immune changes haven't started yet. Users universally report no noticeable effects in this window. Mild GI discomfort is possible if you take the capsule on an empty stomach; eat within 20 minutes of dosing.

Days 5 to 15, Gene expression accumulation: Epigenetic changes in thymic epithelial cells and lymphocytes are building. T-cell differentiation markers (CD3+, CD4+) should begin shifting if the mechanism is active, but you can't detect this without bloodwork. A small number of users report subtle energy or clarity improvements when stacking with other Khavinson bioregulators, though separating this from placebo is difficult.

Days 15 to 30, End of standard course: This is where the published data lives. Khavinson's clinical observation reported 82% immunogram normalization (CD4+/CD8+ ratio) after full treatment courses in elderly patients, compared to 56% in the standard-treatment control group. Some community users describe feeling "more resilient" to illness; independent verification of these subjective reports is essentially absent.

Months 1 to 6 post-course, Carry-over period: The off-cycle. Khavinson's model holds that epigenetic changes in immune cells persist well beyond the dosing period. The three to six month break lets you confirm that immune improvements are self-sustaining before the next course. Independent data on carry-over duration is minimal. Longevity protocol users report continued immune stability for months, though attributing this specifically to Crystagen is difficult.

Detailed Timeline: Science vs Community

Days 1–5
Science

No measurable immune changes yet. Peptide begins interacting with immune cell gene promoter regions per Khavinson epigenetic model.

Community

Users universally report no noticeable effects in the first few days: consistent with the slow epigenetic mechanism.

Days 5–15
Science

Epigenetic changes in thymic epithelial cells and lymphocytes begin to accumulate. T-cell differentiation markers (CD3+, CD4+) should begin shifting if the mechanism is active.

Community

A minority of users report early subtle improvements in energy or mental clarity when stacked with other bioregulators; most report no change. Difficult to distinguish from placebo.

Days 15–30
Science

82% immunogram normalization (CD4+/CD8+ ratio) reported at end of full treatment course in elderly patients in Khavinson clinical observation (vs. 56% in standard-treatment control group).

Community

Some users report feeling "more resilient" to illness; anecdotal immune resistance to cold/flu reported via product-page testimonials. Independent verification essentially absent.

Months 1–6 (post-course)
Science

Khavinson theory holds that epigenetic changes in immune cells persist well beyond the dosing period. The 3–6 month off-period allows assessment of whether immune improvements are self-sustaining.

Community

Minimal independent data. Longevity-protocol users report continued immune stability for months post-course, though this is difficult to attribute specifically to Crystagen.

Pharmacokinetics

Half-Life
1h
Bioavailability
Oral: estimated 1-10% based on general tripeptide pharmacokinetics
Tmax
Estimated 30-60 minutes oral
Data Confidence
low

Source: Estimated from ultrashort peptide kinetics; no direct PK studies on Crystagen published.

Pharmacokinetics: Active Dose Over Time

t½ = ~0.5-2 hours (estimated, ultrashort peptide)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
3
Sequence
EDP
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: Not assigned (synthetic research peptide, no CAS registered)

Who Should Consider Crystagen

  • Individuals over 50 experiencing age-related immune decline
  • Researchers studying Khavinson bioregulator peptides and thymic immunomodulation
  • People interested in oral peptide bioregulators as an alternative to injectable thymic peptides
  • Those with recurrent infections seeking immune support under medical supervision

Related Peptides

What Changed for Crystagen

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations

References

  1. [1]Effects of short peptides on thymocyte blast transformation and signal transduction (Khavinson et al., 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process (Adv Gerontol 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Effects of short peptides on lymphocyte chromatin in senile subjects (Khavinson et al., 2004) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store capsules at room temperature (15-25°C) in a dry place, away from direct sunlight
After Reconstitution
N/A — supplied as oral capsules
Temperature
15-25°C (59-77°F)

Frequently Asked Questions

Thymalin is the parent polypeptide extract from which Crystagen (Glu-Asp-Pro) was isolated. Thymalin is a complex mixture of thymic peptides requiring IM injection; Crystagen is a single synthetic tripeptide available in oral capsules. Crystagen represents the "synthetic cytogen" generation; more defined, more convenient, but with a thinner evidence base than the parent extract.

Yes, theoretically. By activating T-cell and B-cell populations and shifting CD4+/CD8+ ratios, Crystagen could amplify autoimmune processes in susceptible individuals. The contraindication for active autoimmune disease is appropriate and represents the most clinically relevant safety concern.

Genuinely uncertain. Oral bioavailability is estimated at 1–10%, standard for tripeptides not engineered for absorption. Khavinson's group argues that even small absorbed quantities trigger gene regulatory cascades, but independent verification of oral bioavailability and resulting immune changes is lacking.

The entire Khavinson bioregulator program originates at the St. Petersburg Institute of Bioregulation and Gerontology. Western researchers have not independently replicated these findings. This single-group dependency is a legitimate scientific concern; it doesn't mean the data is fabricated, but replication is needed before high-confidence claims can be made.

The 82% immunogram normalization figure comes from a full 30-day course in elderly patients. Bloodwork (lymphocyte counts, CD4+/CD8+ ratio) is required to objectively measure effects; subjective immune "feeling" is unreliable. Measurable changes require 15–30 days.